Galderma Group AGGALD.SW
What Galderma Group AG does.
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $3.8B | $4.1B | $4.4B | $5.2B |
| Net income | — | -$98.5M | -$57.0M | $231.0M | $613.0M |
| Free cash flow | — | -$48.2M | $12.0M | $213.0M | $1.0B |
More on GALD.SW.
- Galderma Group AG summary
- Galderma Group AG financial statements
- Galderma Group AG key metrics
- Galderma Group AG health scores
- Galderma Group AG valuation
- Galderma Group AG dividends
- Galderma Group AG peers
- Galderma Group AG annual reports
Figures from Galderma Group AG's annual reports (ESEF, via filings.xbrl.org) and Yahoo Finance, standardised automatically; prices are end-of-day closes. Not financial advice.